Use of buprenorphine in HIV-infected injection drug users: negligible impact on virologic response to HAART. The Manif-2000 Study Group.
Some HIV-infected injecting drug users (IDUs) on drug abuse maintenance treatment have access to highly active antiretroviral therapy (HAART); this raises questions about the effects of individual treatments on the efficacy of HAART. The French Cohort Study of HIV-infected IDUs - MANIF-2000 - allowed one to assess whether buprenorphine differentially impacts efficacy of HAART. Of the 103 HAART-treated patients, (excluding active IDUs and patients on methadone), 20 were on buprenorphine substitution treatment and 83 were ex-IDUs. A linear regression model used the differences in viral load titre before and after treatment initiation, as a dependent variable, and showed that buprenorphine treatment was not significantly associated with viral load trend. This was also the case when adjusting for other potential confounders, and suggests that there is no major short-term influence of buprenorphine on HIV viral load in HAART-treated patients.
Carrieri
M P
MP
INSERM research Unit 379 'Epidemiology and Social Sciences Applied to Medical Innovation', Institut Paoli Calmettes, 23 rue Stanislas Torrents, Marseille, France.
Vlahov
D
D
Dellamonica
P
P
Gallais
H
H
Lepeu
G
G
Spire
B
B
Obadia
Y
Y
D000328:Adult; D002047:Buprenorphine / Q000627:therapeutic use*; D015331:Cohort Studies; D005260:Female; D005602:France; D015658:HIV Infections / Q000188:drug therapy* / Q000209:etiology; D006801:Humans; D016014:Linear Models; D008297:Male; D009294:Narcotics / Q000627:therapeutic use*; D018709:Statistics, Nonparametric; D015819:Substance Abuse, Intravenous / Q000150:complications / Q000188:drug therapy*; D019562:Viral Load
D009294:Narcotics; D002047:Buprenorphine